LUPRON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUPRON (LUPRON).
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
| Metabolism | Primarily metabolized by peptidases in the liver and kidneys; no significant CYP450 involvement. |
| Excretion | Renal (primarily as metabolites), <5% unchanged; fecal ~5% |
| Half-life | Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged |
| Protein binding | Approximately 40-50% bound to plasma proteins (mainly albumin) |
| Volume of Distribution | 0.3-0.5 L/kg; distributes mainly into extracellular fluid; higher Vd in elderly |
| Bioavailability | Subcutaneous: ~90-100%; intramuscular: ~100%; intranasal: only investigative (not approved) |
| Onset of Action | Subcutaneous: suppression of LH and FSH within 2-4 weeks; intramuscular: similar; initial transient stimulation phase lasts about 1 week |
| Duration of Action | Subcutaneous depot formulations: 1-4 months depending on formulation; IM depot: 1-3 months; clinical effects persist for duration of dosing |
| Molecular Weight | 1269.47 |
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | For central precocious puberty: Weight-based dosing. Body weight ≤25 kg: 7.5 mg intramuscularly every 28 days; >25 to 37.5 kg: 11.25 mg intramuscularly every 28 days. Alternatively, 0.3 mg/kg intramuscularly every 28 days. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity in elderly patients. |
| 1st trimester | Leuprolide is contraindicated in pregnancy; may cause fetal harm. Risk of miscarriage or fetal abnormalities based on animal studies and its mechanism of action (GnRH agonist). |
| 2nd trimester | Contraindicated in pregnancy; continued exposure may disrupt fetal development. |
| 3rd trimester | Contraindicated in pregnancy; risks include potential hormonal disruption. |
Clinical note
Comprehensive clinical and safety monograph for LUPRON (LUPRON).
| Placental transfer | Leuprolide is a peptide and likely crosses the placenta, though specific data are limited. Animal studies indicate transfer and fetal effects. |
| Breastfeeding | Leuprolide is not recommended during breastfeeding. It may suppress lactation or affect the infant due to potential hormonal effects. No adequate human data available. |
■ FDA Black Box Warning
WARNING: LUPRON has been associated with an increased risk of myocardial infarction, sudden cardiac death, and stroke in men with prostate cancer. Androgen deprivation therapy may contribute to cardiovascular risk.
| Serious Effects |
PregnancyHypersensitivity to leuprolide or any component of the formulationUndiagnosed abnormal vaginal bleedingUse in women who may become pregnant
| Precautions | Cardiovascular disease risk (MI, stroke, sudden cardiac death), Hyperglycemia and diabetes risk, Bone density loss and osteoporosis, QT prolongation risk, Seizure risk in patients with CNS disorders, Tumor flare reaction initially in prostate cancer, Hypersensitivity reactions, Spinal cord compression in prostate cancer |
| Food/Dietary | No significant food interactions reported. However, due to potential hyperglycemic effects, patients should be advised to avoid excessive intake of high-sugar foods and maintain a balanced diet to manage blood glucose levels. Concomitant alcohol use may exacerbate hot flashes and vasomotor symptoms; therefore, moderate or avoid alcohol during treatment. |
Loading safety data…
| Lactation Rating |
| L5 - Contraindicated |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: High risk of spontaneous abortion and major congenital malformations, including neural tube defects and cardiovascular anomalies. Second/third trimesters: Continued risk of fetal harm, including potential for delayed fetal development and endocrine disruption. Contraindicated in pregnancy. |
| Fetal Monitoring | Pregnancy test before initiating therapy; confirm non-pregnant status. Monitor for signs of pregnancy during treatment (e.g., missed menses). If pregnancy occurs, discontinue immediately and assess fetal wellbeing via ultrasound and maternal serum markers. Monitor maternal bone mineral density if prolonged use. |
| Fertility Effects | Suppresses pituitary-ovarian axis, inhibiting ovulation and potentially impairing fertility during treatment. Effects are reversible upon discontinuation. May cause temporary infertility. In females, resumption of ovulation typically occurs within weeks to months after cessation. |
| Clinical Pearls | LUPRON (leuprolide acetate) is a GnRH agonist used for androgen deprivation therapy in prostate cancer, central precocious puberty, endometriosis, and uterine fibroids. Initial flare phenomenon can exacerbate symptoms (e.g., bone pain, urinary obstruction) for the first 1-2 weeks; consider antiandrogen coverage (e.g., bicalutamide) during initiation. For injection site reactions, apply local cold packs. Monitor serum testosterone levels in prostate cancer: target <50 ng/dL. In central precocious puberty, confirm diagnosis with GnRH stimulation test before starting. Depot formulations provide sustained release for 1, 3, 4, or 6 months; verify formulation and injection interval. Contraindicated in pregnancy (Category X); obtain negative pregnancy test before use. Risk of QT prolongation; monitor electrolytes and EKG in at-risk patients. May cause hyperglycemia and diabetes; monitor blood glucose. Bone density loss with long-term use; ensure adequate calcium and vitamin D intake. |
| Patient Advice | This medication is given as an injection under the skin or into a muscle, usually every 1 to 6 months depending on the formulation. · Initially, symptoms may temporarily worsen for about 1-2 weeks due to a surge in hormone levels; contact your doctor if you experience severe pain, difficulty urinating, or changes in vision. · For prostate cancer: report any new or worsening bone pain, especially in the spine or hips, as this may require additional treatment. · For central precocious puberty: monthly injections are typically given until the child reaches an appropriate age for puberty (around 10-11 years). · This drug can cause hot flashes, night sweats, decreased libido, erectile dysfunction, and mood changes. These effects are usually reversible after stopping treatment. · Women of childbearing age must use effective contraception during treatment and for 2 months after the last injection; do not breastfeed. · Long-term use may weaken bones; take calcium (1,000-1,200 mg daily) and vitamin D (800-1,000 IU daily) supplements, and perform weight-bearing exercises. · Monitor for signs of high blood sugar: increased thirst, frequent urination, or fatigue. Report these to your doctor. · Avoid alcohol excess as it may worsen vasomotor symptoms (hot flashes). · Do not skip doses; missed injections can lead to return of symptoms. Keep all appointments for injections. |